Vertex Pharmaceuticals Stock Return On Equity

VRTX Stock

USD 450.37 0.86 0.19%

Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Return On Equity	0.21	0.22

Return On Equity is likely to rise to 0.22 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Vertex Pharmaceuticals Company Return On Equity Analysis

Vertex Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Vertex Pharmaceuticals Return On Equity

-0.0298

Most of Vertex Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Vertex Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Vertex Stock properly, considering its historical fundamentals such as Return On Equity. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Common Stock	Long Term Debt	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.98	0.94	0.99	1.0	-0.07	0.98	0.99	0.37	0.04	0.23	0.93	0.2	0.83	0.44	0.99	0.08	0.66	-0.55	0.78	0.79	0.93	0.92	0.78
Total Stockholder Equity	1.0		-0.98	0.95	0.98	1.0	-0.08	0.97	0.99	0.35	0.01	0.22	0.92	0.21	0.84	0.44	1.0	0.06	0.66	-0.56	0.79	0.79	0.94	0.92	0.78
Net Debt	-0.98	-0.98		-0.94	-0.96	-0.99	0.1	-0.95	-0.99	-0.34	0.0	-0.13	-0.89	-0.24	-0.84	-0.45	-0.99	0.02	-0.66	0.55	-0.79	-0.68	-0.96	-0.97	-0.69
Retained Earnings	0.94	0.95	-0.94		0.89	0.94	-0.07	0.93	0.93	0.07	-0.14	0.12	0.79	0.1	0.76	0.58	0.94	-0.07	0.44	-0.35	0.63	0.81	0.9	0.89	0.79
Total Liab	0.99	0.98	-0.96	0.89		0.99	-0.02	0.98	0.98	0.47	0.12	0.27	0.94	0.19	0.81	0.43	0.97	0.17	0.68	-0.55	0.78	0.78	0.91	0.9	0.76
Total Current Assets	1.0	1.0	-0.99	0.94	0.99		-0.08	0.98	0.99	0.37	0.03	0.21	0.93	0.21	0.83	0.44	1.0	0.07	0.65	-0.56	0.78	0.76	0.94	0.94	0.75
Short Term Debt	-0.07	-0.08	0.1	-0.07	-0.02	-0.08		0.02	-0.07	0.02	-0.13	-0.3	-0.03	-0.15	-0.28	0.12	-0.1	-0.05	-0.2	0.24	-0.17	0.09	-0.11	-0.11	0.03
Accounts Payable	0.98	0.97	-0.95	0.93	0.98	0.98	0.02		0.96	0.38	0.1	0.23	0.92	0.18	0.72	0.47	0.96	0.18	0.57	-0.46	0.69	0.82	0.9	0.89	0.8
Net Receivables	0.99	0.99	-0.99	0.93	0.98	0.99	-0.07	0.96		0.37	0.02	0.18	0.91	0.22	0.86	0.45	0.99	0.03	0.67	-0.55	0.8	0.72	0.94	0.94	0.71
Common Stock	0.37	0.35	-0.34	0.07	0.47	0.37	0.02	0.38	0.37		0.6	0.51	0.56	0.28	0.34	-0.1	0.36	0.42	0.72	-0.61	0.48	0.13	0.4	0.38	0.23
Long Term Debt	0.04	0.01	0.0	-0.14	0.12	0.03	-0.13	0.1	0.02	0.6		0.41	0.21	-0.05	0.02	-0.1	0.01	0.87	0.31	-0.23	0.0	-0.04	0.11	0.09	0.06
Short Term Investments	0.23	0.22	-0.13	0.12	0.27	0.21	-0.3	0.23	0.18	0.51	0.41		0.28	-0.06	0.29	0.02	0.21	0.34	0.21	-0.25	0.09	0.25	0.22	0.17	0.27
Property Plant Equipment	0.93	0.92	-0.89	0.79	0.94	0.93	-0.03	0.92	0.91	0.56	0.21	0.28		0.2	0.73	0.16	0.93	0.29	0.77	-0.75	0.79	0.73	0.84	0.83	0.72
Current Deferred Revenue	0.2	0.21	-0.24	0.1	0.19	0.21	-0.15	0.18	0.22	0.28	-0.05	-0.06	0.2		0.06	-0.2	0.25	-0.14	0.43	-0.34	0.55	0.03	0.21	0.18	0.04
Good Will	0.83	0.84	-0.84	0.76	0.81	0.83	-0.28	0.72	0.86	0.34	0.02	0.29	0.73	0.06		0.4	0.83	-0.07	0.68	-0.55	0.76	0.49	0.83	0.81	0.5
Intangible Assets	0.44	0.44	-0.45	0.58	0.43	0.44	0.12	0.47	0.45	-0.1	-0.1	0.02	0.16	-0.2	0.4		0.4	-0.23	-0.06	0.41	0.07	0.41	0.54	0.54	0.5
Net Tangible Assets	0.99	1.0	-0.99	0.94	0.97	1.0	-0.1	0.96	0.99	0.36	0.01	0.21	0.93	0.25	0.83	0.4		0.05	0.68	-0.59	0.8	0.76	0.94	0.93	0.75
Long Term Debt Total	0.08	0.06	0.02	-0.07	0.17	0.07	-0.05	0.18	0.03	0.42	0.87	0.34	0.29	-0.14	-0.07	-0.23	0.05		0.18	-0.22	-0.05	0.19	-0.01	-0.02	0.16
Capital Surpluse	0.66	0.66	-0.66	0.44	0.68	0.65	-0.2	0.57	0.67	0.72	0.31	0.21	0.77	0.43	0.68	-0.06	0.68	0.18		-0.86	0.88	0.37	0.68	0.64	0.47
Deferred Long Term Liab	-0.55	-0.56	0.55	-0.35	-0.55	-0.56	0.24	-0.46	-0.55	-0.61	-0.23	-0.25	-0.75	-0.34	-0.55	0.41	-0.59	-0.22	-0.86		-0.73	-0.28	-0.52	-0.5	-0.3
Short Long Term Debt	0.78	0.79	-0.79	0.63	0.78	0.78	-0.17	0.69	0.8	0.48	0.0	0.09	0.79	0.55	0.76	0.07	0.8	-0.05	0.88	-0.73		0.48	0.73	0.7	0.49
Long Term Investments	0.79	0.79	-0.68	0.81	0.78	0.76	0.09	0.82	0.72	0.13	-0.04	0.25	0.73	0.03	0.49	0.41	0.76	0.19	0.37	-0.28	0.48		0.65	0.59	0.95
Net Invested Capital	0.93	0.94	-0.96	0.9	0.91	0.94	-0.11	0.9	0.94	0.4	0.11	0.22	0.84	0.21	0.83	0.54	0.94	-0.01	0.68	-0.52	0.73	0.65		0.99	0.73
Net Working Capital	0.92	0.92	-0.97	0.89	0.9	0.94	-0.11	0.89	0.94	0.38	0.09	0.17	0.83	0.18	0.81	0.54	0.93	-0.02	0.64	-0.5	0.7	0.59	0.99		0.66
Capital Stock	0.78	0.78	-0.69	0.79	0.76	0.75	0.03	0.8	0.71	0.23	0.06	0.27	0.72	0.04	0.5	0.5	0.75	0.16	0.47	-0.3	0.49	0.95	0.73	0.66

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Vertex Pharmaceuticals

Return On Equity Over Time

Vertex Total Stockholder Equity

Total Stockholder Equity

18.46 Billion

At this time, Vertex Pharmaceuticals' Total Stockholder Equity is fairly stable compared to the past year.

Based on the latest financial disclosure, Vertex Pharmaceuticals has a Return On Equity of -0.0298. This is 99.88% lower than that of the Biotechnology sector and 99.92% lower than that of the Health Care industry. The return on equity for all United States stocks is 90.39% lower than that of the firm.

Vertex Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.

Vertex Pharmaceuticals is currently under evaluation in return on equity category among its peers.

Vertex Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Vertex Fundamentals

	Return On Equity	-0.0298
	Return On Asset	0.12
	Profit Margin	(0.05) %
	Operating Margin	0.41 %
	Current Valuation	111.38 B
	Shares Outstanding	257.53 M
	Shares Owned By Insiders	0.07 %
	Shares Owned By Institutions	96.00 %
	Number Of Shares Shorted	4.5 M
	Price To Earning	24.57 X
	Price To Book	7.43 X
	Price To Sales	10.94 X
	Revenue	9.87 B
	Gross Profit	5.32 B
	EBITDA	4.61 B
	Net Income	3.62 B
	Cash And Equivalents	9.77 B
	Cash Per Share	38.06 X
	Total Debt	808.4 M
	Debt To Equity	0.06 %
	Current Ratio	4.70 X
	Book Value Per Share	60.65 X
	Cash Flow From Operations	3.54 B
	Short Ratio	4.51 X
	Earnings Per Share	(1.90) X
	Price To Earnings To Growth	1.18 X
	Target Price	513.87
	Number Of Employees	5.4 K
	Beta	0.39
	Market Capitalization	116.2 B
	Total Asset	22.73 B
	Retained Earnings	10.14 B
	Working Capital	10.6 B
	Current Asset	1.41 B
	Current Liabilities	506.35 M
	Net Asset	22.73 B

About Vertex Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC